This study investigates metastatic pancreatic cancer. It focuses on understanding how the disease behaves during treatment.
The study evaluates the use of small molecules in the blood, called miRNAs, to see if they can indicate how well the treatment is working.
- Who can participate: Adults 18 years or older diagnosed with metastatic PDAC and starting FOLFIRINOX treatment can participate. Participants must sign an informed consent form.
- Study details: Participants will have blood samples taken to analyze miRNAs.